Analyst Day F e b r u a r y 1 0 t h , 2 0 2 6 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Click to edit Master text Disclaimer This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are subject to risks and uncertainties. Forward-looking statement ...

Core Insights - CorMedix Therapeutics will host an in-person and virtual analyst day on February 10, 2026, to discuss its portfolio and pipeline, highlighting key growth drivers and upcoming milestones [1][2] Company Overview - CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [4] - The company is commercializing DefenCath® for the prevention of catheter-related bloodstream infections and has a portfolio of anti-infective products following its acquisition of Melinta Therapeutics [4] Product Pipeline - CorMedix's REZZAYO® program is in Phase III for the prophylaxis of fungal infections, while DefenCath® is in Phase III for reducing CLABSI in adult patients receiving Total Parenteral Nutrition [2][5] - Topline results for the Phase III study of REZZAYO are expected in Q2 2026 [5] Event Details - The analyst day will feature key opinion leaders and senior management discussing market dynamics and unmet medical needs [2] - A live question-and-answer session will follow the presentations, with in-person attendance limited to analysts and institutional investors [3]